We operate under GMP certifications from INVIMA and ANVISA, ensuring safe and effective products tailored to the strict requirements of highly regulated markets like Brazil and Europe.
We specialize in the production of active pharmaceutical ingredients and finished products with cannabinoids, including pharmaceutical-grade CBD, for the treatment of conditions such as chronic pain, anxiety, insomnia, and neurological disorders.
We work closely with B2B partners, the medical community, and pharmaceutical companies to deliver innovative therapies to patients worldwide. From development to large-scale production, we adapt to the needs of each project, ensuring impactful and effective health solutions.
We collaborate with research centers, regulators, and healthcare professionals to advance cutting-edge therapies, with active clinical studies in insomnia, ensuring every treatment is supported by scientific evidence and meets the highest global quality standards.
Serial entrepreneur with over 20 years of experience founding and scaling businesses across various industries including fintech, retail, education, and logistics. His ability to structure companies and attract investment has been key to the growth of Tarkus Pharma Lab.
Executive with over 15 years in the pharmaceutical industry, CEO of Calox International, the leading generics company in Central America and Venezuela. His expertise in regulation, distribution, and strategy has helped Tarkus Pharma Lab establish itself as a key player in the sector.
Strategy and business development specialist with over 15 years of experience in consulting and business management. Formerly at Accenture and Bekaert, he has led expansion projects across Latin America, optimizing operations and maximizing opportunities for Tarkus in regulated markets.
We focus on offering natural alternatives to address complex conditions where traditional treatments may fall short. Our aim is to improve quality of life by providing access to effective, science-backed products that help restore well-being.
We have three core values, carefully chosen to attract the right people and create a positive and productive work environment:
We foster a “Yes we can” mindset in all our team members and collaborators. With determination, effort, and a positive attitude, we believe we can overcome any challenge and achieve our goals.
We value teamwork and collaboration, as we understand that we can achieve exceptional results together. We foster a co-creation environment where each team member contributes their skills and knowledge to develop innovative and effective solutions.
We always pride ourselves on honesty and consistency. We strive to maintain high levels of integrity in all our actions and decisions, ensuring that we fulfill our promises and maintain transparent communication. Our commitment to integrity allows us to build strong and lasting relationships with customers, partners, and constituents.
We turn our culture into action through a clear and effective focus.
Our methodology, ‘Must-Win Battles,’ helps us define clear, achievable goals aligned with our values and purpose. These include:
Our 1,800 m² facility includes over 1,000 m² of ISO 8 clean rooms, allowing us to process more than 5 tons of dried cannabis flower per month. We transform this raw material into Active Pharmaceutical Ingredients (APIs) and ready-to-market formulations for highly regulated markets.
We offer our B2B partners and clients the following services:
Our location within a Free Trade Zone allows us to offer operational efficiency and competitive advantages in cost and export.
We develop natural, safe, and science-backed products to treat chronic pain, anxiety, and neurological disorders. Our approach goes beyond product development: we lead clinical studies in Brazil and Australia to validate new therapies for insomnia and Rett syndrome.
We develop natural, safe, and science-backed products to treat chronic pain, anxiety, and neurological disorders. Our approach goes beyond product development: we lead clinical studies in Brazil and Australia to validate new therapies for insomnia and Rett syndrome.
